New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia-Reference-Cited by-同舟云学术

New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia

Published:2020-01 Issue: Volume:94 Page:103361
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Bertrand Jeanluc,Dostálová Hana,Krystof Vladimir,Jorda Radek,Castro Alejandro,Mella Jaime,Espinosa-Bustos Christian,María Zarate Ana,Salas Cristian O.

Funder

Fondecyt

Ministry of Health of the Czech Republic

Palacký University in Olomouc

European Regional Development Fund

CONICYT

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference46 articles.

1. Current role of genetics in hematologic malignancies Indian;Prakash;J. Hematol. Blood. Transfus,2016

2. Genetic predisposition to hematologic malignancies: management and surveillance;Godley;Blood,2017

3. Oncology, past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy;Rossari;J. Hematol. Oncol.,2018

4. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review;Liang;Eur. J. Med. Chem.,2018

5. A comprehensive review of protein kinase inhibitors for cancer therapy;Kannaiyan;Expert Rev. Anticancer Ther.,2018

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer;Bioorganic Chemistry;2024-10

2. New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs;Pharmaceutics;2024-05-11

3. Metal-free, late-stage nitration strategy to construct 6-(ortho-nitroaryl)amino purine derivatives enabled by t-BuONO;Tetrahedron Letters;2024-03

4. Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy;Current Medicinal Chemistry;2024-02-16

5. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia;Mini-Reviews in Medicinal Chemistry;2023-10-06